VISA of PBMCs. Vector integration sites were determined from PBMC samples obtained ∼2 years after gene therapy at the start of LTFU and from the most recently obtained PBMC sample available to assess changes over the time of LTFU. (A) Stacked bars illustrate the 10 most abundant vector integration sites detected at the times indicated for each patient. (B) Word cloud with names of genes most commonly found with vector integrants across all 10 patients. Relative sizes of the gene names indicate their relative abundance. *Within transcription unit (TU); ^∼within 50 kB of oncogene(s); ^!within 50 kB of gene(s) implicated in human lymphomas; N.B., LMO2 gene name appears twice, representing integrants within the LMO2 TU (denoted with an asterisk) and those adjacent to, but not actually within, the LMO2 TU.